Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically\* or cytologically\* confirmed non-small cell lung cancer
• * Any histology, except squamous cell carcinoma, allowed
• * Mixed tumors will be categorized by the predominant cell type unless small cell elements are present, in which case the patient is ineligible
• * No histology in close proximity to a major vessel or cavitation NOTE: \*Histologic or cytologic elements may be established on metastatic tumor aspirates or biopsy
• Meets 1 of the following stage criteria:
• * Stage IIIB disease (with malignant pleural effusion)
• * Stage IV disease
• * Recurrent disease
• Measurable or non-measurable disease
• No known CNS metastases by CT scan or MRI
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-1
• Life expectancy
• Not specified
• Hematopoietic
• Absolute neutrophil count \> 1,500/mm\^3
• Platelet count \> 100,000/mm\^3
• No history of hemorrhagic disorders
• Hepatic
• Bilirubin \< 1.5 mg/dL
• AST and ALT \< 5 times upper limit of normal
• INR \< 1.5
• PTT normal
• Renal
• Creatinine clearance ≥ 45 mL/min
• Urine protein:creatinine ≤ 1.0 by spot urinalysis
• Cardiovascular
• No myocardial infarction within the past 6 months
• No New York Heart Association class II-IV congestive heart failure
• No unstable angina pectoris
• No serious cardiac arrhythmia requiring medication
• No stroke within the past 6 months
• No peripheral vascular disease ≥ grade 2
• No uncontrolled hypertension (i.e., blood pressure ≥ 150/100 mm Hg)
• * Patients with a history of hypertension allowed provided blood pressure is well controlled on a stable regimen of anti-hypertensive therapy
• No history of thrombotic disorders
• No other clinically significant cardiovascular disease
• Pulmonary
• No history of gross hemoptysis, defined as bright red blood of a ½ teaspoon or more
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Must be willing and able to take daily oral folic acid, intermittent vitamin B\_12 injections, and corticosteroid premedication
• No ongoing or active infection
• No serious, non-healing wound, ulcer, or bone fracture
• No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
• No psychiatric illness or social situation that would preclude study compliance
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• More than 3 weeks since prior immunotherapy
• Chemotherapy
• No prior systemic chemotherapy
• Endocrine therapy
• More than 3 weeks since prior hormonal therapy
• Radiotherapy
• See Disease Characteristics
• More than 3 weeks since prior radiotherapy
• Surgery
• More than 4 weeks since prior major surgery
• More than 1 week since prior minor surgery, fine needle aspiration, or core biopsy
• No concurrent major surgery
• Other
• Recovered from all prior therapy
• More than 4 weeks since prior and no concurrent participation in another experimental drug study
• No aspirin or other nonsteroidal anti-inflammatory drug (NSAID) 2 days before and 2 days after each pemetrexed disodium infusion (5 days before and 2 days after each pemetrexed disodium infusion for NSAIDs with a long half-life \[e.g., naproxen, rofecoxib, or celecoxib\])
• No concurrent therapeutic anticoagulation
• * Concurrent prophylactic anticoagulation for venous access devices allowed provided requirements for INR and PTT are met
• No concurrent administration of any of the following:
• * Chronic daily treatment with aspirin (\> 325 mg per day)
• * NSAIDs known to inhibit platelet function, including any of the following:
• * Dipyridamole
• * Ticlopidine
• * Clopidogrel
• * Cilostazol